One industry that’s getting a tax hike in 2018: medical devices
While much of corporate America will enjoy a tax cut in the new year, one industry is getting a tax increase it fought hard to avoid.
A 2.3% excise tax on medical device manufacturers is set for reinstatement Monday after a two-year hiatus. It was originally imposed in 2013 as one of several taxes and fees in the Affordable Care Act that pay for expanded health insurance under the law.
The tax was strongly opposed by the $150-billion-a-year industry that produces items such as catheters, heart stents and artificial joints. In Congress, it was unpopular not only with Republicans, but with many Democrats from states such as Massachusetts and Minnesota, which have large numbers of medical device companies.
Congress voted to suspend the tax for 2016 and 2017 with the widespread expectation that it would be permanently abolished before 2018. But various GOP efforts to repeal the Affordable Care Act and the taxes associated with it failed, and the sweeping federal tax overhaul recently signed by President Trump didn’t eliminate the medical device tax either.
Industry groups such as the Advanced Medical Technology Assn, or AdvaMed, and the Medical Imaging & Technology Alliance warn the tax will take a $20-billion bite out of the industry over the next decade.
“What we have seen from past experience is that it comes out of funding for product development, research and the jobs associated with those things,” said J.C. Scott, AdvaMed’s head of government affairs. “We fear we will see employment freezes or reductions and a slowdown in the pipeline for medical innovation.”
The slashing of the overall corporate tax from 35% to 21% may soften the blow for some manufacturers, industry officials say, but not for all. As the excise tax is applied to sales and not income, it will fall harder on smaller firms and start-ups with promising new products that have yet to yield profits.
Supporters of the tax contend manufacturers have overstated both the harm suffered while the tax was in effect, and the potential impact of its resumption. They argue expansion of health coverage under the ACA benefited medical device makers by boosting the potential market for their products and note that other sectors — including private insurers and pharmaceutical companies — also pay taxes and fees toward the health law and complain less about them.
Device makers certainly aren’t giving up their fight. They still hold out hope of repealing or again suspending the tax.
Despite earlier failures, industry officials say congressional backing for repeal remains strong. The next attempt could come in connection with a spending bill needed by Jan. 19 to avert a government shutdown.
Boston Scientific, a leading maker of heart stents and other devices, estimates reinstatement of the tax will cost the Marlborough, Massachusetts-based firm $75 million in 2018. The company said that when the tax was suspended, it invested the savings in projects, including a partnership with the Mayo Clinic that combines manufacturing expertise with ideas from physicians for new products to help patients.
“The reinstatement of the device tax threatens continued investment in programs like these,” Boston Scientific said in a statement.
Some Democrats, including Sen. Elizabeth Warren (D-Mass.), have said they won’t support repeal of the tax unless an equivalent source of revenue is found for the ACA.
In a Dec. 20 letter to Trump, AdvaMed urged the president to support repeal of the tax and, in the interim, to direct the IRS to grant companies “administrative relief” from the tax. That could include such steps as waiving the bimonthly deposit requirement or any penalties resulting from late payments.
“Retroactive action by Congress next year cannot fully undo the impact of allowing this tax to be triggered on Jan. 1,” the companies wrote.
The view from Sacramento
Sign up for the California Politics newsletter to get exclusive analysis from our reporters.
You may occasionally receive promotional content from the Los Angeles Times.